Unfortunately, no molecule directly targeting STAT3 has received Food and Drug Administration (FDA) approval for any pathology so far [122], and candidate compounds targeting viral disease have not advanced beyond preclinical evaluation (Table 2). This evidence concerns the gene STAT3 and viral infectious disease.